Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method Therefor

Patent No. EP3470400 (titled "Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method Therefor") was filed by Crystal Pharmaceutical Suzhou on Jun 14, 2017. The application was issued on Apr 2, 2025.

Patent Summary

Crystalline forms of ozanimod and its hydrochloride salt, and methods for their preparation. The crystalline forms are designated as CS1, CS2, CS3, CS5, and CS6, which exhibit unique solid-state structures that enable stable and consistent pharmaceutical formulations. The crystalline forms are prepared through a process that involves selective crystallization from a solvent system comprising alcohols, nitriles, and esters, followed by filtration, evaporation, and solidification. The crystalline forms are characterized by their distinct crystal structures and properties, which are critical for maintaining the drug's stability and bioavailability during storage and processing.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BRAND MURRAY FULLERJan 2, 2026BRAND MURRAY FULLER
ADALVODec 30, 2025SLAVIK
DR SCHONDec 23, 2025DR SCHON
SANDOZDec 23, 2025KRAUS & LEDERER PARTGMBB
SYNTHONDec 19, 2025HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3470400

CRYSTAL PHARMACEUTICAL SUZHOU
Application Number
EP17812728A
Filing Date
Jun 14, 2017
Status
Granted And Under Opposition
Feb 28, 2025
Publication Date
Apr 2, 2025